Everolimus
Everolimus is an active ingredient of the class «ALK inhibitor».
Chemical compound
Boxed warning (US label)
MALIGNANCIES, SERIOUS INFECTIONS, KIDNEY GRAFT THROMBOSIS, NEPHROTOXICITY and MORTALITY IN HEART TRANSPLANTATION Malignancies and Serious Infections Only physicians experienced in immunosuppressive therapy and management of transplant patients should…
What it is used for
- Islet cell carcinoma
- Tuberous sclerosis 1
- Benign neoplasm of brain
- Low-grade astrocytoma
- Angiomyolipoma
- Carcinoid syndrome
- Kidney cancer
- Acute myeloid leukemia
- Diffuse large B-cell lymphoma
- Lymphoma
- Neuroendocrine tumor
- Kidney angiomyolipoma
- Small intestine carcinoma
- Renal clear cell carcinoma
- Neuroendocrine carcinoma
- Carcinoid tumor
- Breast cancer
- Renal cell carcinoma
- Breast neoplasm
- Neoplasm
Zortress is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving a: Kidney Transplant: At low-moderate immunologic risk.
Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumour size or…
How it works
- FK506-binding protein 1A inhibitor
Class: ALK inhibitor
Common side effects
The most common adverse reactions were as follows: Kidney Transplantation (incidence greater than or equal to 20%): peripheral edema, constipation, hypertension, nausea, anemia, urinary tract infection (UTI), and hyperlipidemia Liver Transplantation (incidence greater than 10%): diarrhea, headache, peripheral edema…
Who should not take it
Hypersensitivity Reactions Zortress is contraindicated in patients with known hypersensitivity to everolimus, sirolimus, or to any of its excipients.
Pregnancy and breastfeeding
Based on animal studies and the mechanism of action, Zortress can cause fetal harm when administered to a pregnant woman.
Interactions
Brand names
United States
Afinitor · Afinitor Disperz · Zortress
European Union
Afinitor · Votubia
Canada
Afinitor · Afinitor Disperz · Certican · Nat-Everolimus · Pms-Everolimus · Reddy-Everolimus · Sandoz Everolimus · Teva-Everolimus
Approval status
- US Food and Drug Administration
- prescription · since 2009
- European Medicines Agency
- authorised · since 2009
- Health Canada
- prescription · marketed
- First approval anywhere
- 2009
Codes
- ATC
- L01EG02, L01XE10, L04AA18, L04AH02
- RxNorm CUI
- 141704
- ChEMBL
- CHEMBL1908360
- PubChem CID
- 6442177
- UNII
- 9HW64Q8G6G
- Wikidata
- Q421052
Frequently asked questions
What is Everolimus used for?
Everolimus is used for: Islet cell carcinoma, Tuberous sclerosis 1, Benign neoplasm of brain, Low-grade astrocytoma, Angiomyolipoma, Carcinoid syndrome, Kidney cancer, and Acute myeloid leukemia.
What kind of medicine is Everolimus?
Everolimus is an active ingredient of the class «ALK inhibitor».
What are the brand names of Everolimus?
Brand names of Everolimus include Afinitor, Afinitor Disperz, Zortress, Votubia, Certican, Nat-Everolimus, Pms-Everolimus, and Reddy-Everolimus.
Medicines in the same class
- Sirolimus
- Imatinib
- Gefitinib
- Dasatinib (anhydrous)
- Afatinib
- Erlotinib
- Sunitinib
- Nilotinib
- Crizotinib
- Adalimumab
- Leflunomide
- Fingolimod
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)